Report cover image

Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published May 31, 2022
Length 68 Pages
SKU # GMD17226473

Description

Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Drugs In Development, 2022, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 4, 4, 8, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

68 Pages
Introduction
Global Markets Direct Report Coverage
Drug Overdose – Overview
Drug Overdose – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose – Companies Involved in Therapeutics Development
Amphastar Pharmaceuticals Inc
Avior Bio Inc
Clear Scientific LLC
Crossject SA
Egetis Therapeutics AB
Emergent BioSolutions Inc
Enalare Therapeutics Inc
Fab’entech SA
Hepione Therapeutics Inc
Icure Pharmaceutical Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Nasus Pharma Ltd
Opiant Pharmaceuticals Inc
Orexo AB
ResQ Pharma Inc
Sparian Biosciences Inc
Vallon Pharmaceuticals Inc
Vernalis R&D Ltd
Worphmed Srl
Drug Overdose – Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning – Drug Profile
drinabant – Drug Profile
ENA-001 – Drug Profile
IXTf-250 – Drug Profile
IXTM-200 – Drug Profile
melatonin – Drug Profile
nalmefene – Drug Profile
naloxone – Drug Profile
naloxone hydrochloride – Drug Profile
naloxone hydrochloride 1 – Drug Profile
naloxone. – Drug Profile
OPNT-006 – Drug Profile
physostigmine – Drug Profile
PP-100 – Drug Profile
SBS-371 – Drug Profile
Small Molecule for Acute Opioid Overdosage – Drug Profile
Small Molecule for Drug Overdose and Drug Toxicity – Drug Profile
Small Molecules for Alzheimer's Disease and Drug Overdose – Drug Profile
Small Molecules for Substance Abuse and Drug Overdose – Drug Profile
V-24343 – Drug Profile
Vaccine for Drug Overdose – Drug Profile
Drug Overdose – Dormant Projects
Drug Overdose – Discontinued Products
Drug Overdose – Product Development Milestones
Featured News & Press Releases
Apr 01, 2022: Anebulo Pharmaceuticals doses more than half of the subjects in part A of a phase 2 clinical trial and provides guidance on IND submission
Feb 08, 2022: Teva agrees to pay $225m to settle opioid claims in Texas
Jan 03, 2022: Anebulo Pharmaceuticals announces initiation of phase 2 clinical study evaluating ANEB-001 for the treatment of acute cannabinoid intoxication
Dec 20, 2021: Klaria Pharma initiates clinical study with Naloxon Alginate Film
Dec 02, 2021: Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film
Nov 16, 2021: Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
Oct 22, 2021: Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering naloxone alginate film
Oct 13, 2021: Anebulo Pharmaceuticals announces issuance of U.S. patent covering use of ANEB-001 for the treatment of acute Cannabinoid overdose
Sep 13, 2021: Anebulo Pharmaceuticals announces completion of manufacturing of ANEB-001 capsules for upcoming phase 2 clinical trial
Jul 16, 2021: Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Apr 13, 2021: Nasus Pharma announces positive results in pivotal trial of FMXIN001 Naloxone powder-based nasal spray for the treatment of opioid overdose
Feb 08, 2021: Opiant Pharmaceuticals announces first patient dosed in confirmatory pharmacokinetic study assessing OPNT003, nasal nalmefene, for the treatment of opioid overdose
Feb 05, 2021: Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film
Jan 29, 2021: Orexo expects FDA filing of OX124 mid 2022
Jan 27, 2021: Orexo strengthens IP rights for overdose rescue drug OX124
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Drug Overdose, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022 (Contd..1)
Table 6: Products under Development by Universities/Institutes, 2022
Table 7: Number of Products by Stage and Target, 2022
Table 8: Number of Products by Stage and Mechanism of Action, 2022
Table 9: Number of Products by Stage and Route of Administration, 2022
Table 10: Number of Products by Stage and Molecule Type, 2022
Table 11: Drug Overdose – Pipeline by Amphastar Pharmaceuticals Inc, 2022
Table 12: Drug Overdose – Pipeline by Avior Bio Inc, 2022
Table 13: Drug Overdose – Pipeline by Clear Scientific LLC, 2022
Table 14: Drug Overdose – Pipeline by Crossject SA, 2022
Table 15: Drug Overdose – Pipeline by Egetis Therapeutics AB, 2022
Table 16: Drug Overdose – Pipeline by Emergent BioSolutions Inc, 2022
Table 17: Drug Overdose – Pipeline by Enalare Therapeutics Inc, 2022
Table 18: Drug Overdose – Pipeline by Fab’entech SA, 2022
Table 19: Drug Overdose – Pipeline by Hepione Therapeutics Inc, 2022
Table 20: Drug Overdose – Pipeline by Icure Pharmaceutical Inc, 2022
Table 21: Drug Overdose – Pipeline by InterveXion Therapeutics LLC, 2022
Table 22: Drug Overdose – Pipeline by Klaria Pharma Holding AB, 2022
Table 23: Drug Overdose – Pipeline by Mucodel Pharma LLC, 2022
Table 24: Drug Overdose – Pipeline by Nasus Pharma Ltd, 2022
Table 25: Drug Overdose – Pipeline by Opiant Pharmaceuticals Inc, 2022
Table 26: Drug Overdose – Pipeline by Orexo AB, 2022
Table 27: Drug Overdose – Pipeline by ResQ Pharma Inc, 2022
Table 28: Drug Overdose – Pipeline by Sparian Biosciences Inc, 2022
Table 29: Drug Overdose – Pipeline by Vallon Pharmaceuticals Inc, 2022
Table 30: Drug Overdose – Pipeline by Vernalis R&D Ltd, 2022
Table 31: Drug Overdose – Pipeline by Worphmed Srl, 2022
Table 32: Drug Overdose – Dormant Projects, 2022
Table 33: Drug Overdose – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Drug Overdose, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Top 10 Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us